Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate
Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate
Esperion Therapeutics第一季度每股收益0.34美元超過預期的0.05美元，銷售額1.3774億美元超過8451萬美元的預期
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.05 by 580 percent. This is a 143.04 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $137.74 million which beat the analyst consensus estimate of $84.51 million by 62.98 percent. This is a 466.14 percent increase over sales of $24.33 million the same period last year.
Esperion Therapeutics（納斯達克股票代碼：ESPR）公佈的季度收益爲每股0.34美元，比分析師普遍預期的0.05美元高出580％。這比去年同期每股虧損0.79美元（0.79美元）增長了143.04％。該公司公佈的季度銷售額爲1.374億美元，比分析師普遍預期的8,451萬美元高出62.98％。這比去年同期的2433萬美元的銷售額增長了466.14％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。